Ifinatamab deruxtecan
- Generic Name
- Ifinatamab deruxtecan
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2484870-92-8
- Unique Ingredient Identifier
- C6I0GC0GX5
- Associated Conditions
- -
- Associated Therapies
- -
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Phase 1
Recruiting
- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 123
- Registration Number
- NCT06362252
- Locations
- 🇫🇷
Assistance Publique-Hă"Pitaux de Marseille, Marseille, France
🇫🇷Chu Nantes - Hă"Pital Guillaume Et Renă Laă<Nnec, Saint Herblain, France
🇫🇷Hă"Pital Foch, Suresnes Cedex, France
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Phase 2
Recruiting
- Conditions
- Recurrent or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 520
- Registration Number
- NCT06330064
- Locations
- 🇺🇸
Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Pih Health Hematology Medical Oncology, Whittier, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath